Compare TDW & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDW | CPRX |
|---|---|---|
| Founded | 1956 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | N/A | 2006 |
| Metric | TDW | CPRX |
|---|---|---|
| Price | $76.76 | $23.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $82.00 | $35.00 |
| AVG Volume (30 Days) | 879.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | N/A | ★ 1.68 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | $1.12 | $8.00 |
| Revenue Next Year | $5.56 | $9.77 |
| P/E Ratio | $24.08 | ★ $13.91 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $31.17 | $19.05 |
| 52 Week High | $88.99 | $26.56 |
| Indicator | TDW | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 41.69 |
| Support Level | $47.73 | $22.46 |
| Resistance Level | $82.00 | $24.86 |
| Average True Range (ATR) | 4.03 | 0.97 |
| MACD | -1.06 | -0.11 |
| Stochastic Oscillator | 16.37 | 28.16 |
Tidewater Inc provides marine and transportation services to the offshore energy industry. The company's vessels and associated services support all phases of offshore crude oil and natural gas (also referred to as oil and gas) exploration activities, field development, production, and maintenance, as well as windfarm development and maintenance. Its services include towing and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workovers, production activities, field abandonment, dismantlement, and restoration activities; and Others. The group manages its business through five segments including the Americas, Asia Pacific, Middle East, Europe/Mediterranean, and West Africa.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.